Scientific Publications
On this page you find a selection of scientific publications relating to the product candidates and platform technologies of MOLOGEN AG.
| 2015 | ||
MIDGE technology for the Production of a Fourfold Gene-Modified, Allogenic Call-Based Vaccine for Cancer Therapy | Schmidt M et al. Gene Therapy of Solid Cancers, Methods in Molecular Biology, Volume 1317, 2015, pp 39-51 | Link |
Sequential chemo-immunotherapy of experimental visceral leishmaniasis using single low dose liposomal amphotericin B and a novel DNA vaccine candidate. | Seifert K et al. Antimicrob. Agents Chemother. 2015 0 (2015), p. AAC. 00273-15v1 | Link |
| Local and systemic effect of transfection-reagent formulated DNA vectors on equine melanoma. | Mählmann K et al. BMC Veterinary Research 2015, 11:107 doi: 10.1186/s 12917-015-0414-9 | Link |
| Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703. | Schmidt M et al. Nucleic Acid Therapeutics. doi:10.1089 / nat.2015.0533. | Link |
| Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine | Riede O et al. Gene Therapy advance online publication 30 April 2015; doi: 10.1038/gt.2015.35 | Link |
| MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside. | Wittig B et al.Critical Reviews in Oncology/Hematology, 2015. | Link |
| Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours. | Weihrauch MR et al.Eur J Cancer 51 (2): 146–156, 2015. | Link |
| 2014 | ||
| A subgroup of metastatic colorectal cancer patients with very prolonged disease control under maintenance therapy with the TLR-9 agonist MGN1703. | J. Riera-Knorrenschild et al. Ann. Oncol., 25 (suppl. 2): ii8 (abstract PD-0009), 2014. | Link |
| The randomized phase III IMPALA study: Immunomodulatory maintenance therapy with TLR-9 agonist MGN1703 in patients with metastatic colorectal cancer carcinoma. | D. Cunningham et al. Ann. Oncol., 25 (suppl. 2): ii98 (abstract PD-0268), 2014. | Link |
| ASET study: Final results of patients with locally recurrent or metastatic renal cell carcinoma (RCC) treated with MGN1601. | V. Grünwald et al. Ann. Oncol., 25 (suppl. 4): iv366-iv367 (abstract 1063P), 2014. | Link |
| IMPACT study: A subgroup of metastatic colorectal cancer patients with very prolonged disease control under maintenance therapy with the TLR-9 agonist MGN1703. | W. Scheithauer et al. Ann. Oncol., 25 (suppl. 4): iv366 (abstract 1061P), 2014. | Link |
| Immunomodulatory maintenance therapy with TLR-9 agonist MGN1703 in patients with metastatic colorectal carcinoma - the randomized phase III IMPALA study. | D. Arnold et al. Ann. Oncol., 25 (suppl. 4): iv371 (abstract 1077TiP), 2014. | Link |
| Cationic Lipid-Formulated DNA Vaccine against Hepatitis B Virus: Immunogenicity of MIDGE-Th1 Vectors Encoding Small and Large Surface Antigen in Comparison to a Licensed Protein Vaccine | Endmann A et al. DOI:10.1371/journal.pone.0101715, July 2014 | Link |
| Genuine Immunomodulation with dSLIM. | Kapp K et al. Molecular Therapy - Nucleic Acids (2014) 3, e170, epub June 24, 2014 | Link |
| IMPACT trial – Predictive factors for maintenance therapy with MGN1703 in patients with metastatic colorectal carcinoma. | Riera-Knorrenschild J et al. J Clin Oncol. 32 (suppl.): 5s (abstract: 3615), 2014 | Link |
| Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. | Schmoll HJ et al. J Cancer Res Clin Oncol. [Epub ahead of print, 2014 May] | Link |
| Combination of MIDGE-Th1 DNA vaccines with the cationic lipid SAINT-18: Studies on formulation, biodistribution and vector clearance. | Endmann A et al. Vaccine. 2014; 32(27): 3460-7 | Link |
| Preclinical study on combined chemo- and nonviral gene therapy for sensitization of melanoma using a human TNF-alpha expressing MIDGE DNA vector. | Kobelt D et al. Mol Oncol. 2014; 8(3):609-19 | Link |
| Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis. | Das S et al. Sci Transl Med. 2014; 6(234): 234-56 | Link |
| Conformation overrides base sequence - insights from a novel class TLR-9 agonists. | Kapp K et al. AACR 2014, abstract no. 2565 | Link |
| ASET study: Long-term follow-up data of patients with metastatic renal cell carcinoma treated with MGN1601. | Grünwald V et al. J Clin Oncol. 32 (4, suppl.): (abstract LBA399), 2014 | Link |
2013 | ||
| Updated results of the randomized phase 2 IMPACT trial: Maintenance with TLR-9 agonist MGN1703 vs placebo in patients with metastatic colorectal carcinoma (mCRC). | Schmoll HJ et al. Ann Oncol. 24 (suppl . 4): iv16-iv17 (abstract: O-0012), 2013 | Link |
| Maintenance with the TLR-9 agonist MGN1703 versus placebo in patients with advanced colorectal carcincoma (mCRC): A randomized phase II trial (IMPACT). | Riera-Knorrenschild J et al. J Clin Oncol. 31 (15, suppl 1): (abstract: 3643), 2013 | Link |
| MGN1703 – structure of agonist determines cellular responses to TLR9 activation. | Kapp K et al. ASGCT 16th Annual Meeting (May 15 – May 18, 2013). (abstract: 686) 2013 | Link |
| Can anthocyanins improve maintenance therapy of Ph(+) acute lymphoblastic leukaemia? | Köchling J et al. Eur J Haematol. 2013; 90(4): 291-300 | Link |
| Identification of biomarkers for overall survival of patients with metastatic renal cell carcinoma treated with MGN1601. | Grünwald V et al. J Clin Oncol. 31 (6, suppl.): (abstract 468), 2013 | Link |
2012 | ||
| Maintenance treatment with immunomodulator MGN1703 following induction with standard 1st line therapy prolongs progression-free survival in patients with metastatic colorectal (mCRC): results of the phase II/III IMPACT trial. | Arnold D et al. Ann Oncol. 23 (suppl. 9): ix178 (abstract: 518O), 2012 | Link |
| The novel cancer vaccine, consisting of genetically modified allogeneic tumor cells and immunomodulator MGN1601: Updated results of a phase 1-2 study in patients with advanced renal cell carcinoma. | Schmidt-Wolf IGH et al. Ann Oncol. 23 (suppl. 9): ix268 (abstract: 813P), 2012 | Link |
| Prevention and synergistic control of Ph(+) ALL by a DNA vaccine and 6-mercaptopurine. | Köchling J et al. Vaccine. 2012; 30(41): 5949-55 | Link |
| Efficacy and safety of cancer vaccine with 4-fold gene-modified allogeneic tumor cells: Results of the phase I/II ASET study in patients with advanced renal cell carcinoma. | Weikert S et al. J Clin Oncol. 30 (15, suppl 1): (abstract: 4636), 2012 | Link |
| Intratumoral Dispersion, Retention, Systemic Biodistribution, and Clearance of a Small-Size Tumor Necrosis Factor-a-Expressing MIDGE Vector after Nonviral in Vivo Jet-Injection Gene Transfer. | Galling et al. Hum Gene Ther Methods. 23: 264-270, 2012 | Link |
| Preliminary Safety Results from the IMPACT Study – A Phase 2-3 Clinical Study in Patients with Advanced Colorectal Carcincoma with the Immunomodulator MGN1703. | Schmidt M et al. Mol Ther. 20 (suppl. 1): S262 (abstract: 679), 2012 | Link |
| New Safety and Efficacy Data of a Phase 1-2 Study in Patients with Advanced Renal Cell Carcinoma, Following Vaccination with Fourfold Gene-Modified, Allogeneic Tumor Cells Combined with a DNA-Based Immunomodulator. | Weikert S et al. Mol Ther. 20 (suppl 1): S129 (abstract: 327), 2012 | Link |
| Immune-related efficacy data of the phase 1-2 study of an with fourfold gene-modified allogeneic tumor cell based vaccine in patients with advanced renal cell carcinoma. | Weith E et al. Cancer Res. 72 (8, suppl. 1): (abstract: LB-233), 2012 | Link |
| New safety and efficacy data of the ongoing phase I/II study (ASET Study) with an allogeneic tumor vaccine and adjuvant in patients with metastatic renal cell carcinoma. | Grünwald V et al. J Clin Oncol. 30 (5, suppl.): (abstract 398), 2012 | Link |
| IMPACT study: A phase II-III clinical study with the immunomodulator MGN1703 in patients with advanced colorectal carcincoma. | Tschaika M et al. Clin Oncol. 30 (4, suppl.): (abstract: 633), 2012 | Link |
Archive | ||
| Immune response induced by a linear DNA vector: influence of dose, formulation and route of injection. | Endmann A et al. Vaccine. 2010; 28(21): 3642-9 | Link |
| Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia. | Köchling J et al. Vaccine. 2008; 26(36): 4669-75 | Link |
| Minimal size MIDGE vectors improve transgene expression in vivo. | Schakowski F et al. In Vivo. 2007; 21(1):17-23 | Link |
| MIDGE/hNIS vaccination generates antigen-associated CD8+IFN-gamma+ T cells and enhances protective antitumor immunity. | Choi Y et al. Int J Cancer. 2007; 120(9): 1942-50 | Link |
| Effect of different nuclear localization sequences on the immune responses induced by a MIDGE vector encoding bovine herpesvirus-1 glycoprotein D. | Zheng C et al. Vaccine. 2006; 24(21): 4625-9 | Link |
| MIDGE Vectors and dSLIM Immunomodulators: DNA-based Molecules for Gene Therapeutic Strategies, in Modern Biopharmaceuticals. | Schmidt M et al. J. Knäblein and R.H. Müller, Editors. 2005, WILEY-VCH Verlag GmbH&Co. KGaA: Weinheim. 1-29. | |
| DNA immunisation with minimalistic expression constructs. | Moreno S et al. Vaccine. 2004; 22(13-14): 1709-16 | Link |
| Protection of mice against Philadelphia chromosome-positive acute lymphoblastic leukemia by cell-based vaccination using nonviral, minimalistic expression vectors and immunomodulatory oligonucleotides. | Köchling J et al. Clin Cancer Res. 2003; 9(8): 3142-9 | Link |
| DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. | López-Fuertes L et al. Vaccine. 2002; 21(3-4): 247-57 | Link |
| Priming of immune responses to hepatitis B surface antigen with minimal DNA expression constructs modified with a nuclear localization signal peptide. | Schirmbeck R et al. J Mol Med (Berl). 2001; 79(5-6): 343-50 | Link |
| Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial. | Wittig B et al. Hum Gene Ther. 2001; 12(3): 267-78 | Link |
| Form Follows Function, in Plasmid for Therapy and Vaccination. | Junghans C et al. M. Schleef, Editor 2001, Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim. 139-156 |
Related Links
Contact:
Dr. Matthias Schroff
[email protected]